Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)

使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)

基本信息

项目摘要

PROJECT SUMMARY for MPRINT CET ADMINISTRATIVE CORE The primary goal of the UCSD MPRINT CET is to serve as a national resource for knowledge and expertise in maternal and pediatric pharmacology. The Multi-PI leadership of the UCSD MPRINT CET, who will lead three Research Projects and two Support Cores (Milk Analytics and Pharmacometrics) excels in research fields of maternal and infant health, human milk, antibiotic therapeutics, pharmacometrics, metabolomics and microbiome. In order to successfully execute the goals of this program, we have formulated an Administrative Core that will facilitate the research activities and provide timely and responsible oversight of the UCSD MPRINT CET. The Specific Aims of the Administrative Core are: Aim 1: Provide leadership and oversight for the UCSD MPRINT CET to maximize effective execution of the research program and achieve all deliverables and milestones. The Administrative Core leadership (Drs. Tremoulet and Chambers) and program manager (Kristin Woods) have exceptional track-records in administration of multisite networks and will coordinate communication and overall cohesiveness among the various elements of the UCSD MPRINT CET and MPRINT Hub. The Administrative Core will oversee the preparation of annual reports and publications, as well as handle ongoing critical evaluation and outcomes assessment to achieve continual improvement of the MPRINT CET effectiveness. In so doing the Administrative Core will optimize evaluation, reprioritization and adjustment of activities, timelines and milestones. This Core will provide continuous and accurate financial management by tracking the financial status of the UCSD MPRINT CET Projects, Cores, and Support Pool. Aim 2: Facilitate the interactions of the UCSD MPRINT CET that will maximize the contributions to the MPRINT Hub The Administrative Core leadership will identify emerging needs across the UCSD MPRINT CET to choose Support Pool projects that will enhance the MPRINT Hub's role as a national resource in pediatric and maternal clinical pharmacology. The Administrative Core will lead the effort to select the most meritorious and impactful Support Pool projects. This Core will also be responsible for all communication with the MPRINT's Knowledge and Research Coordination Center (KRCC) and support outreach and dissemination of new knowledge by coordinating with the MPRINT KRCC's Outreach, Dissemination, and Training Core. Finally, the Administrative Core will provide an integrated educational and practical mentored research training experience in maternal and pediatric clinical pharmacology for health sciences professionals interested in becoming leaders in the field. In achieving these aims, the Administrative Core will achieve its mission of fostering communication and collaboration across the Research Projects and Cores at UCSD, as well as coordinate closely with the MPRINT KRCC and the entire MPRINT Hub.
MPRINT CET管理核心项目总结 UCSD MPRINT CET的主要目标是作为国家知识和专业知识资源 母儿药理学。UCSD MPRINT CET的多重PI领导,谁将领导三个 研究项目和两个支持核心(牛奶分析和药物计量学)在以下研究领域表现出色 母婴健康、母乳、抗生素疗法、药物计量学、代谢组学和 微生物组。为了顺利执行这一计划的目标,我们制定了一项管理 将促进研究活动并对UCSD MPRINT进行及时和负责任的监督的核心 CET。行政核心的具体目标是:目标1:领导和监督 UCSD MPRINT CET以最大限度地有效执行研究计划并实现所有交付成果 和里程碑。行政核心领导层(特雷姆莱特博士和钱伯斯博士)和项目经理 (克里斯汀·伍兹)在多站点网络管理方面有着出色的记录,并将协调 UCSD、MPRINT、CET和MPRINT各要素之间的沟通和整体凝聚力 集线器。行政核心将监督年度报告和出版物的编写,并处理 持续进行关键评估和结果评估,以实现MPRINT CET的持续改进 有效性。在这样做的过程中,行政核心将优化评价、重新确定优先次序和调整 活动、时间表和里程碑。该核心将通过以下方式提供持续和准确的财务管理 跟踪UCSD MPRINT CET项目、核心和支持池的财务状况。目标2:促进 UCSD MPRINT CET的互动将最大限度地发挥对MPRINT枢纽的贡献 管理核心领导层将确定整个UCSD MPRINT CET的新兴需求,以选择支持 将加强MPRINT中心作为儿科和孕产妇临床国家资源的集合项目 药理学。行政核心将领导选择最有价值和最有影响力的支持的努力 泳池项目。该核心还将负责与MPRINT所知和 研究协调中心(KRCC),并通过以下方式支持推广和传播新知识 与MPRINT KRCC的外联、传播和培训核心进行协调。最后,行政部门 CORE将提供综合的教育和实践指导的研究培训经验 面向有志于成为该领域领导者的健康科学专业人员的儿科临床药理学。在……里面 为了达到这些目标,行政核心将实现其促进沟通和 在UCSD的研究项目和核心之间进行协作,并与MPRINT密切协调 KRCC和整个MPRINT枢纽。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADRIANA H TREMOULET其他文献

ADRIANA H TREMOULET的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADRIANA H TREMOULET', 18)}}的其他基金

Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10487509
  • 财政年份:
    2021
  • 资助金额:
    $ 19.63万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10309712
  • 财政年份:
    2021
  • 资助金额:
    $ 19.63万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9096853
  • 财政年份:
    2014
  • 资助金额:
    $ 19.63万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9216033
  • 财政年份:
    2014
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    8123189
  • 财政年份:
    2007
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7490096
  • 财政年份:
    2007
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7673722
  • 财政年份:
    2007
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7908694
  • 财政年份:
    2007
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7338088
  • 财政年份:
    2007
  • 资助金额:
    $ 19.63万
  • 项目类别:
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases
炎症和传染病的儿科和发育药理学
  • 批准号:
    9355662
  • 财政年份:
  • 资助金额:
    $ 19.63万
  • 项目类别:

相似海外基金

Culture change in international organizations: Exammining corporate annual reports of Japanese and US corporations
国际组织的文化变迁:审视日本和美国企业的年度报告
  • 批准号:
    20K01874
  • 财政年份:
    2020
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of the value of textual information in annual reports through natural language processing
通过自然语言处理分析年报文本信息的价值
  • 批准号:
    18K18566
  • 财政年份:
    2018
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysing Narrative Aspects of UK Preliminary Earnings Announcements and Annual Reports: Tools and Insights for Researchers and Regulators
分析英国初步收益公告和年度报告的叙述方面:研究人员和监管机构的工具和见解
  • 批准号:
    ES/R003904/1
  • 财政年份:
    2017
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Research Grant
The Design of Corporate Annual Reports in London, 1980-2000
1980-2000 年伦敦公司年度报告的设计
  • 批准号:
    1937453
  • 财政年份:
    2017
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Studentship
Making a database of statistical appendices to Annual Reports of the Poor Law Commissioners and those of the Poor Law Board and the analysis of the database.
建立济贫法专员和济贫法委员会年度报告的统计附录数据库,并对数据库进行分析。
  • 批准号:
    16530240
  • 财政年份:
    2004
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Econological Approach toward Annual Reports
年度报告的经济方法
  • 批准号:
    07630123
  • 财政年份:
    1995
  • 资助金额:
    $ 19.63万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ANNUAL REPORTS
年度报告
  • 批准号:
    3701612
  • 财政年份:
    1994
  • 资助金额:
    $ 19.63万
  • 项目类别:
ANNUAL REPORTS
年度报告
  • 批准号:
    3701614
  • 财政年份:
    1994
  • 资助金额:
    $ 19.63万
  • 项目类别:
ANNUAL REPORTS
年度报告
  • 批准号:
    3701609
  • 财政年份:
    1994
  • 资助金额:
    $ 19.63万
  • 项目类别:
ANNUAL REPORTS
年度报告
  • 批准号:
    3701611
  • 财政年份:
    1994
  • 资助金额:
    $ 19.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了